Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

13.05USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$13.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
147,256
52-wk High
$18.95
52-wk Low
$11.90

Latest Key Developments (Source: Significant Developments)

Vanda receives negative opinion for marketing authorization from the European Medicines Agency
Friday, 10 Nov 2017 04:05pm EST 

Nov 10 (Reuters) - Vanda Pharmaceuticals Inc ::Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍CHMP re-examined its negative opinion and confirmed refusal of fanaptum MAA​.  Full Article

Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Vanda Pharmaceuticals Inc :Qtrly ‍net loss per share $0.10​.  Full Article

Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds
Wednesday, 18 Oct 2017 07:34am EDT 

Oct 18 (Reuters) - Vanda Pharmaceuticals Inc :Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds.Vanda Pharmaceuticals - Pricing agreement for treatment of totally blind individuals with sleep-wake disorder with Hetlioz after an arbitration board decision.Vanda Pharmaceuticals - ‍Ex-factory price of Hetlioz in Germany expected to be about eur 69,000/year, effective date of Aug 1, 2017​ - SEC Filing.  Full Article

Vanda Pharmaceuticals qtrly ‍net loss per share $0.03​
Wednesday, 2 Aug 2017 04:01pm EDT 

Aug 2 (Reuters) - Vanda Pharmaceuticals Inc :Vanda Pharmaceuticals Inc - ‍total net product sales were $42.1 million in Q2 of 2017​.Vanda Pharmaceuticals Inc - qtrly ‍net loss per share, basic and diluted $ 0.03​.Q2 earnings per share view $-0.28, revenue view $40.3 million -- Thomson Reuters I/B/E/S.Sees ‍2017 combined net product sales from both Hetlioz and Fanapt between $165 million to $175 million​.  Full Article

Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum
Friday, 21 Jul 2017 07:00am EDT 

July 21 (Reuters) - Vanda Pharmaceuticals Inc :Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍Vanda intends to appeal this opinion and request a re-examination by CHMP​.Vanda Pharmaceuticals Inc - ‍CHMP was of opinion that "benefits of Fanaptum did not outweigh its risks" and recommended against marketing authorization​.  Full Article

Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceuticals Inc
Monday, 19 Jun 2017 04:46pm EDT 

June 19 (Reuters) - Vanda Pharmaceuticals Inc :Armistice Capital Llc reports a 5.1 percent passive stake in Vanda Pharmaceuticals Inc as of June 7 - sec filing.  Full Article

Vanda and UCSF announce license agreement for CFTR activators and inhibitors
Wednesday, 29 Mar 2017 05:40pm EDT 

Vanda Pharmaceuticals Inc - : Vanda and UCSF announce license agreement for CFTR activators and inhibitors . Under terms of deal, vanda will pay UCSF an initial license fee of $1 million and will be responsible for all development costs . In 2017 intends to complete technology transfer activities from UCSF,initiate ind enabling studies for several CFTR indications .To acquire exclusive worldwide license from UCSF to develop, commercialize portfolio of cftr activators, inhibitors.  Full Article

Vanda Pharma settles Fanapt patent litigation with Apotex
Wednesday, 7 Dec 2016 06:45pm EST 

Vanda Pharmaceuticals Inc : Vanda Pharmaceuticals settles Fanapt® patent litigation with Apotex .Agreement provides for full settlement and release by Vanda and Apotex of all claims that are subject of litigation.  Full Article

Vanda says U.S. District Court ruled Roxane Laboratories infringed certain patents
Thursday, 25 Aug 2016 02:51pm EDT 

Vanda Pharmaceuticals Inc :U.S. District Court ruled that Roxane Laboratories infringed U.S. patent nos. RE39,198 and 8,586,610 by submitting to FDA an ANDA.  Full Article

Vanda Pharmaceuticals Q2 loss per share $0.11
Wednesday, 27 Jul 2016 04:01pm EDT 

Vanda Pharmaceuticals Inc : Vanda pharmaceuticals reports second quarter 2016 financial results . Vanda reiterates 2016 net product sales guidance of $143 million to $153 million . Qtrly loss per share $0.11; revenue $36.03 million . Says reiterates its prior 2016 financial guidance . Hetlioz net product sales grew to $17.5 million , fanapt net product sales grew to $18.6 million in q2 2016 .Says year end 2016 cash is expected to be between $123 and $143 million.  Full Article

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia